Stockscreener 앱 받기
4.04
0.75%
0.03
시간 외 거래:
4.02
-0.02
-0.50%
전일 마감가:
$4.01
열려 있는:
$3.94
하루 거래량:
428.07K
Relative Volume:
0.51
시가총액:
$513.26M
수익:
$81.36M
순이익/손실:
$-142.62M
주가수익비율:
-3.3641
EPS:
-1.2009
순현금흐름:
$-146.97M
1주 성능:
-7.13%
1개월 성능:
-4.27%
6개월 성능:
+18.13%
1년 성능:
+121.98%
1일 변동 폭
$3.92
$4.09
1주일 범위
$3.92
$4.56
52주 변동 폭
$1.05
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
명칭
Adc Therapeutics Sa
전화
41 21 653 02 00
주소
BIOPOLE, EPALINGES
Compare ADCT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
4.04 | 509.45M | 81.36M | -142.62M | -146.97M | -1.2009 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 개시 | Guggenheim | Buy |
| 2023-08-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-04-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 개시 | CapitalOne | Overweight |
| 2022-11-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-08-17 | 재개 | Jefferies | Buy |
| 2021-08-09 | 개시 | RBC Capital Mkts | Outperform |
| 2021-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 개시 | Stifel | Hold |
| 2020-10-29 | 개시 | H.C. Wainwright | Buy |
| 2020-06-09 | 개시 | BofA/Merrill | Buy |
| 2020-06-09 | 개시 | Cowen | Outperform |
모두보기
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
ADC Therapeutics (ADCT) Reports 2025 Revenue of $73.6M With Cash Runway Into 2028 - Yahoo Finance
US Stocks Recap: Can ADC Therapeutics SA disrupt its industryRate Hike & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Heights Capital Management Inc. Has $1.31 Million Position in ADC Therapeutics SA $ADCT - MarketBeat
Growth Recap: Will ADC Therapeutics SA benefit from rate cuts2026 Dividend Review & Technical Entry and Exit Tips - baoquankhu1.vn
Fed Watch: Is ADC Therapeutics SA stock showing strong momentumMarket Rally & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
[EFFECT] ADC Therapeutics SA SEC Filing - Stock Titan
ADC Therapeutics (ADCT) registers 9.83M shares issuable on HCR warrants - Stock Titan
ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones - MSN
ADC Therapeutics SA $ADCT Stock Holdings Reduced by Prosight Management LP - MarketBeat
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Wall Street Recap: Can ADC Therapeutics SA expand its profit margins2026 Setups & Growth Focused Investment Plans - baoquankhu1.vn
ADC Therapeutics (NYSE:ADCT) Shares Down 9.2%Should You Sell? - MarketBeat
ADC Therapeutics SA Hits New 52-Week High of $4.95, Up 31.87% - Markets Mojo
ADC Therapeutics SA: 2025 Annual Report Highlights – ZYNLONTA Pipeline, Global Partnerships, and Antibody-Drug Conjugate Innovation - Minichart
ADC Therapeutics SA (ADCT) Reports Wider Loss Q4 EPS Estimates by 85.1% - AlphaStreet
ADC Therapeutics SA 2025 Q4ResultsEarnings Call Presentation (NYSE:ADCT) 2026-03-11 - Seeking Alpha
Aug Shorts: Can ADC Therapeutics SA continue delivering strong returns2026 PreEarnings & Weekly Stock Breakout Alerts - baoquankhu1.vn
ADC Therapeutics reports Q4 revenue of $22.3 million By Investing.com - Investing.com Canada
ADC Therapeutics (NYSE:ADCT) Reaches New 12-Month High Following Strong Earnings - MarketBeat
According to the latest filings submitted to the U.S. Securities and Exchange Commission (SEC), some shareholders of the biopharmaceutical company ADC Therapeutics SA may gradually sell their holdings of the company's common stock over a period of tim - Bitget
ADC Therapeutics 2025 10-K: $81.4M Revenue, $(1.12) EPS - TradingView
[ARS] ADC Therapeutics SA SEC Filing - Stock Titan
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
ADC Therapeutics Q4 2025 Earnings Call Insights - Intellectia AI
ADC Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
ADC Therapeutics SA Files 8-K Report Detailing Company Information and Common Shares Listing on NYSE - Minichart
ADC Therapeutics Q4 Earnings Call Highlights - MarketBeat
ADC Therapeutics (NYSE:ADCT) Shares Gap Up After Strong Earnings - MarketBeat
ADC Therapeutics Narrows Losses, Supported By Higher Product Revenue And Ongoing Restructuring - RTTNews
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance - MSN
ADC Therapeutics reports Q4 revenue of $22.3 million - Investing.com
ADC Therapeutics SA reports results for the quarter ended December 31Earnings Summary - TradingView
ADC Therapeutics SA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Finan - GuruFocus
ADC Therapeutics (NYSE:ADCT) Announces Earnings Results - MarketBeat
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
ADC Therapeutics Q4 Revenue $23.06M Beats Expectations - Intellectia AI
ADC Therapeutics reports Q4 revenue $22.3M, FY2025 revenue $73.6M; cash $261.3M - TradingView
ADC Therapeutics (NYSE: ADCT) cuts 2025 loss and extends cash runway to 2028 - Stock Titan
ADC THERAPEUTICS SA -REDH ($ADCT) Releases Q4 2025 Earnings - Quiver Quantitative
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update - PR Newswire
Earnings Scheduled For March 10, 2026 - Benzinga
Earnings Risk: Can ADC Therapeutics SA continue delivering strong returns2026 Selloffs & Scalable Portfolio Growth Ideas - baoquankhu1.vn
ADC Therapeutics SA (ADCT) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
What to Expect from ADC Therapeutics's Earnings - Benzinga
ADC Therapeutics SA (ADCT) Q4 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
Why ADC Therapeutics SA stock remains a top recommendationJuly 2025 Retail & Low Drawdown Momentum Ideas - Naître et grandir
Will ADC Therapeutics SA stock split again soonTrade Entry Report & Safe Entry Trade Reports - Naître et grandir
Valuation Update: What drives ADC Therapeutics SAs stock priceJuly 2025 WrapUp & Target Return Focused Stock Picks - baoquankhu1.vn
ADC Therapeutics SA expected to post a loss of 27 cents a shareEarnings Preview - TradingView
ADC Therapeutics (ADCT) to Release Earnings on Tuesday - MarketBeat
Adc Therapeutics Sa (ADCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):